Phase 2 Study Finds Evidence of Slowed Disease Progression in Huntington’s Patients
Sep 22, 2016 11:32 am | Daniela Semedo, PhD
Teva Pharmaceutical presented encouraging top-line data from PRIDE-HD, a Phase 2 clinical trial evaluating the impact of pridopidine, an oral medication, on motor impairment in patients with Huntington’s disease (HD). Teva is now preparing for a larger clinical study in Huntington’s. The presentation took place at the 9th European Huntington Disease Network Plenary Meeting in The Hague, Netherlands on Sept. 18. […]
The post Phase 2 Study Finds Evidence of Slowed Disease Progression in Huntington’s Patients appeared first on Huntington's Disease News.